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In conjunction with the rise in rates of obesity, there has been an increase in the rate of nonalcoholic fatty liver disease (NAFLD).
While NAFLD at least partially originates from poor diet, there is a lack of nutritional recommendations for patients with suspected
or confirmed diagnosis of NAFLD, beyond eating a healthy diet, increasing physical activity, and emphasising weight loss. The
limited current literature suggests that there may be opportunities to provide more tailored dietary advice for people diagnosed
with or at risk of NAFLD. Epidemiological studies consistently find associations between whole grain intake and a reduced risk
of obesity and related diseases, yet no work has been done on the potential of whole grains to prevent and/or be a part of the
treatment for fatty liver diseases. In this review, we examine the potential and the current evidence for whole grains having an
impact on NAFLD. Due to their nutrient and phytochemical composition, switching from consuming mainly refined grains to
whole grains should be considered as part of the nutritional guidelines for patients diagnosed with or at risk for fatty liver disease.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the major
liver diseases worldwide. Estimates of average prevalence
vary from around 20–46% of the adult population in West-
ernised countries [1–3], with up to 45% in some ethnic groups
[3, 4]. The prevalence of NAFLD increases up to 90% in
obese populations, and given the worldwide rise in obesity,
the incidence of NAFLD is likely to grow over the coming
decades. While hepatic steatosis, an early stage of NAFLD, is
often asymptomatic, in 20–30% of all cases, it can progress
to nonalcoholic steatohepatitis (NASH). If untreated, NASH
can progress to hepatic cirrhosis and reduced liver function
and increased risk of early mortality [5]. Hepatic steatosis
is characterised by a large number of fatty deposits in the
liver. Critically, NAFLD in the hepatic steatosis phase can
be reversed by lifestyle modification, while NASH is more
difficult to treat though it can be reversed by bariatric surgery
[6]. Thus, preventing the progression of hepatic steatosis to
NASH is of primary importance.
Insulin resistance and oxidative stress are currently con-
sidered the primary mediators of NASH [7]. Other causes
of NASH include total parenteral nutrition, certain drugs
and industrial toxins, copper toxicity, and conditions charac-
terized by extreme insulin resistance [8]. Peripheral insulin
resistance leads to increased delivery of fatty acids to the
liver, and high levels of circulating insulin interfere with
the normal capacity of hepatic mitochondrial 𝛽-oxidation
to metabolize fatty acids; these steps in turn lead to fat
accumulation in the liver [9]. NASH most likely develops
from a subsequent “second hit” whereby oxidative stress leads
to lipid peroxidation in the liver [10]. Mitochondrial dysfunc-
tion and, more specifically, respiratory chain deficiency may
also mediate the second hit by generating reactive oxygen
specieswhich oxidise fat deposits to release lipid peroxidation
products toxic to hepatocytes and other hepatic cells [11].
The increase in oxidative stress and lipid peroxidation leads
to greater inflammation, leading to activation of tumour
necrosis factor-𝛼 and interleukin-6 mediated pathways and
down regulation of hepatocyte autophagy (mitophagy, i.e.,
2 International Journal of Endocrinology
including the process of removing damaged mitochondria)
[12].
While hepatic steatosis in itself may not lead to notice-
able symptoms, the development of NASH is associated
with significant morbidity and mortality and has limited
therapeutic options [13–15]. The main causes of increased
mortality among patients with NASH are cardiovascular
disease, cancer, and liver failure [12]. Patients with NAFLD
are at increased risk for other chronic diseases, including type
2 diabetes and cardiovascular disease [16, 17].
Key risk factors for NAFLD include (1) positive energy
balance (excess energy intake and/or reduced physical activ-
ity), (2) obesity, (3) insulin resistance, and (4) hypertriglyc-
eridemia. These factors are key targets for prevention and
therapy of NAFLD though clinical treatment tends to focus
on addressing the obesity or insulin resistance rather than
NAFLD itself. As with all lifestyle-related diseases, improve-
ment of diet should also play a role in its prevention and
treatment.
The clinical diagnosis of NAFLD requires a liver biopsy;
however, blood biomarkers (alanine aminotransferase and
aspartate aminotransferase) [25] are commonly used in large-
scale epidemiological studies that have examined the link
between diet composition andNAFLD.While thesemeasures
have low specificity, they provide some indirect insight into
the effects of diet on liver function. Presently, it is known
that a high percentage of energy from fat, and especially
saturated fat, may lead to liver damage and that high gly-
caemic foods and refined sugar and fructose may also lead
to hepatic steatosis through increased de novo lipogenesis
[26]. There is mixed evidence on the role of vitamins, with
some suggestions that better vitamin D and E status is linked
to lower incidence of NAFLD, but intervention studies that
have examined the effects of vitamin E supplementation on
NASH did not show conclusive improvement [7, 27, 28].
These studies have been supplemented with 𝛼-tocopherol in
an attempt to treat NASH, which does not rule out a role
for other E vitamers and prevention or treatment of NAFLD.
Studies that have investigated the effects of dietary fat and
carbohydrate have shown that isoenergetic diets with low-fat
and low-carbohydrate diets decrease liver fat, while high-fat
diets increase liver fat over two weeks [29, 30], and increased
protein intake may also reduce intrahepatic lipids [31]. The
mechanisms behind these effects are not well understood,
and the long-term efficacy/safety of low-carbohydrate and
high-protein diets has not been assessed although present
clinical recommendations state that ketogenic diets should
be avoided to prevent greater liver damage. A Mediterranean
diet rich in vegetables, nonred meat protein sources, and
polyunsaturated fat was found to improve insulin sensitivity
and reduce liver fat without weight loss over 6 weeks [32],
and a short-term exercise intervention reduced markers
of NAFLD and apoptosis (alanine aminotransferase and
cytokeratin 18), also without significant weight loss [33],
suggesting that it may be possible to improve NAFLD
without losing weight. Omega-3 fatty acid supplementation
has also been used as a treatment for NAFLD, with some
promising results [26], but it is outside the scope of this
review.
Despite the strong recent efforts in the area of diet
and NAFLD, present lifestyle recommendations for people
diagnosed with NAFLD are generally limited to losing weight
(e.g., through energy restriction) and increasing physical
activity [34], as well as following national guidelines for a
healthy diet [2, 35]. In many countries, this now includes the
recommendation to eat at least half of all grain servings as
whole grains, with gram recommendations ranging from at
least 48 g/d to at least 75 g/2000 kcal [36].
While there are reviews that have covered the area of diet
and physical activity for the treatment of NAFLD [26, 37,
38], none have examined whether increasing whole grains
in the diet may be an effective strategy for prevention and
treatment of NAFLD. This review aims to examine the
evidence supporting the idea that a diet rich in whole grains
is associated with a decrease in many of the risk factors
and comorbidities associated with NAFLD and that replacing
refined grains with whole grains in the diet could also be
an important component of lifestyle changes that could
successfully prevent and treat NAFLD.
2. Whole Grains
Whole grain cereals (whole grains; WG) are consistently
associated with a decreased risk of NAFLD-related diseases,
including obesity, diabetes, and cardiovascular disease [39].
The term “whole grains” covers the edible parts of the
cereal grasses, including wheat, rice, corn, rye, barley, and
oats, and also includes the pseudocereals (seeds that are
used in a similar manner to cereal grains) (Table 1). The
American Association of Cereal Chemists defines whole
grains as cereals that “. . . shall consist of the intact, ground,
cracked, or flaked caryopsis, whose principal anatomical
components—the starchy endosperm, germ, and bran—are
present in the same relative proportions as they exist in
the intact caryopsis” [40]. Over the past 100–150 years, the
most commonly consumed cereals are milled to remove
the bran and the germ from the starch endosperm. This
results in flour that has a longer shelf-life, has better
organoleptic properties, and is easier to process than if
all three components are present [41]. This also results
in flour which is nutrient poor relative to the whole
grain, especially in dietary fibre, vitamins, and minerals,
as well as phytochemicals that may have health benefits
(Table 1). Cereal grains represent one of themain staple foods
worldwide, and improving the quality of cereal foods in
the diet represents an excellent opportunity for improving
health.
While several national dietary guidelines now include
recommendations for increasing whole grain intake and
replacing refined grains with whole grains [36], the aver-
age consumption remains relatively low at around one
16 g serving/d [42–44]. It should be noted that these data
are from surveys taken before the 2005 Dietary Guidelines
for Americans, which placed an increased emphasis on
whole grains [39]. Thus, even though there is an increasing
availability of a wide variety of whole grain foods and greater
public awareness of the potential health benefits of whole
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grains in the diet, recent data suggests that this has not been
translated into greater whole grain consumption [45].
3. Whole Grains and Risk Factors for NAFLD
A considerable body of epidemiological work outlined below
consistently reports that people who eat more whole grains
have a reduced risk of cardiovascular disease, obesity, and
diabetes, while some studies suggest that whole grains may
also reduce markers of inflammation.
Severalmeta-analyses of epidemiological data have found
that increasing whole grain intake reduces the risk of devel-
oping type 2 diabetes in the order of 16–26% compared to
people eating the least amount of whole grains in their diet
[20, 22, 46] (Table 2). Greater intake of whole grains is also
associated with lower fasting C-peptide and insulin although
not glycated haemoglobin (HbA1c) [47]. Recently, greater
whole grain intake was associated with a 34% lower risk of
deteriorating glucose tolerance [48].
A high whole grain intake is also linked to a decreased
likelihood of being obese [49, 50]. There is evidence from
both epidemiological [51] and randomised intervention trials
[52, 53] that abdominal fat mass is reduced on a whole
grain diet compared to refined grains, an effect which has
not been reported for fruits and vegetables [51]. In a meta-
analysis of three major US cohorts, a single serving (assumed
to be 16 g) with an increase in whole grain intake resulted
in a 0.25 kg decrease in body weight over four years, a
small but nevertheless significant change [24]. Eating whole
grains instead of refined grains while on a hypoenergetic
diet does not increase weight loss although it does appear
to improve fat loss [52, 54]. For NAFLD, reduction of body
fat, rather than overall weight loss, may be more important,
making these findings supporting the use of whole grains
as a carbohydrate source during hypoenergetic diets highly
interesting. Mechanisms behind whole grains leading to
preferential loss of body fat remain to be determined.
There are some reports that whole grain intake cor-
relates with reduced concentrations of some inflammation
markers [55, 56] although this is not a universal finding
[47]. Consuming >1 serving of whole grain was associated
with reduced high-sensitivity C-reactive protein (hsCRP) in
premenopausal women [56], while plasminogen activator
inhibitor type 1 (PAI 1) and hsCRP were also decreased
in adults who ate the most whole grains though fibrino-
gen was not associated with whole grain intake [55]. In
women, whole grain intake was associated with reduced
plasma CRP and tumour necrosis factor 𝛼-receptor 2; these
effects were attenuated by waist circumference, insulin sen-
sitivity, and 2 h-postload glucose [57], suggesting a strong
link between inflammation and body composition/insulin
resistance. Overall, epidemiological studies suggest that each
16 g serving of whole grain leads to a 7%decrease in CRP [58].
Evidence from intervention trials is less convincing, with
one study finding reduced CRP in subjects with metabolic
syndrome on a hypocaloric diet while eating whole grains
compared to refined grains [52], and another finding IL-
6 concentrations decreased, especially in overweight and
female subjects as they had higher baseline IL-6 concentra-
tions [59]. However, most other studies that have examined
inflammation parameters have not found significant differ-
ences between refined grain versus whole grain consumption
[60–62].
While epidemiological studies overwhelmingly report
associations between highest intake of whole grains and
reduced risk of cardiovascular diseases, diabetes, and obesity
compared to those eating little or no whole grains [20, 21, 39],
it should be acknowledged that intervention evidence for the
effect ofwhole grains onmarkers of disease risk ismixed, with
a number of studies finding a range of positive biomarker
changes when eating whole grains compared to refined grains
[52–54, 59, 62–66] while other studies have not found any
benefits [60, 61, 67]. In some cases, this may be due to the
difficulty of ensuring compliance in free-living settings [68],
as well as the considerable heterogeneity of study design and
populations used [20]. Meta-analyses of epidemiological and
clinical trials point to an overall effect of diets rich in whole
grains rather than refined grains reducing many of the risk
factors for NAFLD (Table 2).
4. Potential Mechanisms of Action for
Whole Grains in the Prevention
and Treatment of NAFLD
Whole grains are higher in many nutrients and phytochem-
icals than their refined counterparts (Table 1), and several
reviews have described possible mechanisms behind how
they may be better for health [69, 70]. In the context of
prevention or treatment of NAFLD, there are several possible
mechanisms beyond better nutrient intake:
(i) reduction of energy intake (lower energy density
compared to refined foods),
(ii) changes to and stimulation of gut microbiota, leading
to increased production of short-chain fatty acids,
(iii) specific actions of phytochemicals (e.g., vitamins,
phenolic acids, betaine),
(iv) synergistic interaction between different whole grain
components (e.g., phenolic compounds interacting
with stimulated gut microbiota).
In general, whole grain foods are less energy dense
than their refined counterparts, though this depends on the
amount of lipid from the germ; refined grains have the germ
removed and a lower overall fat content. However, lipids
from cereals are mainly unsaturated and so are not a primary
cause for concern for the development ofNAFLD.The slightly
lower (around 5%) amount of carbohydrate in whole grains
compared to refined grains may also reduce the amount of
insulin required to handle the influx of glucose after a meal.
Thehigher amount of fibre has also been suggested to increase
intestinal bulking and thus influence satiety. There is little
data to support an impact of whole grains on satiety [71],
with the exception of rye [72–75]. However, whole grains are
perceived as beingmore satiating by consumers [76], and this
over the long term may reduce energy intake by reducing
portion sizes.
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Several studies have now demonstrated that whole grains
can change gutmicrobiota composition in humans, including
Bifidobacteria and Lactobacillus [59, 66, 77, 78], with corre-
sponding changes to gut microbiota metabolites including
the short-chain fatty acid (SCFA) butyrate measured in
faeces [79, 80] and plasma [81] and phenolic compounds
measured in urine [79, 80]. Increased butyrate production
is linked to improved tissue insulin sensitivity [82–84],
and this may be one mechanism for how whole grains
improve insulin sensitivity (see below). Increasing numbers
of studies have found links between gut microbiota composi-
tion/metabolism and fatty liver disease [85–88], particularly
for the role of lipopolysaccharide (LPS; a cell wall component
of gram negative bacteria) and increased inflammation [89]
and risk for NAFLD and NASH [90, 91]. Prevention of LPS
uptake from the intestinemay be limited by increased intesti-
nal permeability; subjects with NAFLD or NASH are more
likely to have increased intestinal permeability compared to
healthy controls [92, 93]. LPS-induced inflammation via toll-
like receptors has been linked to obesity and is proposed as
a factor in the “second hit” of NAFLD leading to NASH [12].
Low-dose exposure to LPS may also increase hepatic triglyc-
eride production and inhibit triglyceride export at higher
doses [94] through inflammation-mediated interruption of
fatty acid transporters [95]. Recently, it was proposed that
increased circulating leptin leads to a hypersensitive response
to circulating LPS [96], underlining the multitude of factors
influencing the response to gut microbiota components. In
a rat model of alcoholic fatty liver disease, rats fed with an
oat-based diet had less liver fat accumulation than controls,
and this effect was ascribed to thickening of the intestinal
wall, thus preventing excessive ethanol transport across the
intestine [97]. This mechanism may also inhibit transport
of LPS across the intestinal barrier and prevent endotoxin-
associated inflammation. Prebiotic fibre has been linked to
changes in gut microbiota and NAFLD, and this may serve
as another potential mechanism whereby whole grains pro-
tect against NAFLD. The addition of fructooligosaccharide
(FOS) to the diet of mice with fatty liver induced by n-3
polyunsaturated fatty acid deficiency resulted in altered gut
microbiota populations (including increased Bifidobacteria,
as for some whole grain clinical studies [59, 77]) and
reduced hepatic triglyceride accumulation. This effect was
mediated via proliferator-activated receptor 𝛼-stimulation of
fatty acid oxidation, possibly stimulated by the gut hormone
GLP-1 [98]. The composition of gut microbiota and the
integrity of the intestinal barrier may be key factors in
the interaction between diet and NAFLD [89]. Diets rich
in whole grains appear to consistently alter gut microbiota
composition. Beyond the study of Keshavarzian et al. [97], no
studies have examined whether whole grains can improve gut
integrity.
A number of studies have demonstrated lower glycemic
curves following a whole grain diet relative to refined wheat
[81, 99], and the rate of glucose disappearance was increased
in a morning glucose tolerance test after an evening meal
of whole grain barley compared to white rice [100], possibly
indicating improved insulin sensitivity. Beta-cell function
was also found to be improved after a whole grain rye-based
intervention [101]. These apparent improvements in glucose
metabolism may be due to increased fermentation activity of
the gut microbiota, through the action of butyrate, or due
to micronutrients such as magnesium that are present in
relatively high amounts in whole grain. The latter serves as
cofactors for enzymes involved in glucose metabolism and
insulin secretion [102]. It should also be noted that not all
intervention studies have found improvements in markers of
glucose metabolism (e.g., [60, 61]), and the outcomes may be
highly dependent on the study population and design.
There are many phytochemicals that are abundant in
whole grains but are only present in low amounts after refin-
ing. Of particular interest for potential treatment of NAFLD,
whole grain wheat, rye, and quinoa have high amounts of
the methyl donor glycine betaine (trimethylglycine, referred
to henceforth by its common name “betaine”) compared to
other foods [19, 103]. High doses of oral betaine have been
shown to reduce the severity of NAFLD in humans in case
studies [104–106]. However, in one randomised controlled
trial testing betaine supplementation there was no conclusive
evidence for an effect on NASH or inflammation although
betaine did reduce the steatosis grade [107]. The rationale for
the effect of betaine is that it spares choline (which can be
metabolised to betaine for remethylation of homocysteine)
for synthesis into phosphatidylcholine, which in turn is a
key component of VLDL particles for export of lipids from
the liver. If too much choline is required for remethylation
of homocysteine, then export of VLDL from the liver will
be compromised, leading to a buildup of lipids in the liver.
This type of mechanism has been demonstrated in rodent
models of NAFLD where betaine supplementation reduces
the severity of fatty liver in NAFLD models [108]. Higher
plasma homocysteine itself has also been associated with
steatosis and NASH [109, 110], and rodent studies suggest
that Hyperhomocysteinaemia may cause liver damage and
peroxidation [111]. However, elevated plasma homocysteine
has not been associated with steatosis or NASH in all popula-
tions [112, 113], and genetics may play a role in determining
whether hypohomocysteinaemia is a risk factor, especially
for the progression to liver cirrhosis [114]. Whether betaine
supplementation is effective in reducing steatosis or NASH
in cases of hyperhomocysteinaemia is yet to be tested.
Wheat-based foods are the main source of betaine in the
diet and account for 67% of total betaine intake in the New
Zealand diet [103]. Choosing whole grains over refined grains
could increase overall betaine intake by 1.5–3.3 fold. Although
there are no existing recommendations for betaine intake,
choline intake recommendations for adults in the US are
425–550mg/d [115], recognizing that the pathway between
phospholipid synthesis and remethylation of homocysteine is
of importance for general health. It is uncertain what amount
of dietary betaine is required to maintain optimal betaine
status and this is likely to depend on choline and B-vitamin
status as well. A whole grain rich diet (150 g/d) with 112mg/d
more betaine than the control refined grain diet increased
plasma betaine [66] and a very high amount of wheat
aleurone fraction (providing 279mg/d more betaine than
the control) reduced homocysteine and increased betaine,
dimethylglycine, and methionine in healthy adults [116]. In
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The role of whole grains in the prevention of NAFLD
Figure 1: Whole grains may have an impact on nonalcoholic fatty liver disease through many complementary mechanisms. Choosing more
whole grains over refined carbohydrate sources will increase the intake of many nutrients that are known to, or suggested to, play a role in
preventing fatty liver diseases and related comorbidities. While yet to be studied directly, it is probable that a diet rich in whole grains would
play a role in the prevention of fatty liver diseases. Whether they could be a biologically active part of a diet to treat nonalcoholic fatty liver
disease remains to be investigated.
epidemiology, greater whole grain intake has also been asso-
ciatedwith decreased homocysteine [47]. Lowplasmabetaine
and high plasma choline were associated with increased BMI,
body fat, and serum triglyceride, while increased plasma
betaine was associated with increased plasma folate, serum
HDL, and decreased plasma homocysteine [117]. The one-
carbon metabolic pathway may also interact with the gut
microbiota, which may also play an important role in the
development of fatty liver in humans on a choline defi-
cient diet [118]. Given that betaine reverses fatty liver in
rodents on a choline-deficient diet, whole grains as a main
source of dietary betaine and an ingredient that can alter
gut microbiota, mean that several different but interlinked
mechanisms for preventing fatty liver may potentially occur
(Figure 1). Independent of whole grain intake, coeliac disease
may be a risk factor for NAFLD, and elevated concentra-
tions of transaminases are common in people with coeliac
disease [119] though this could also be due to intestinal
damage. The gluten-induced gastrointestinal inflammation
is hypothesised to lead to increased gut leakage [91] and
increased blood LPS, and people diagnosed with NAFLD
and coeliac disease often improve after they are placed on a
gluten-free diet. Monitoring coeliac disease is suggested for
NAFLD patients, even when no other metabolic risk factor
is present [119]. This being the case, it should be noted that
cereals that form the basis of gluten-free diets (i.e., avoidance
of wheat, rye, barley and oats) are generally very low in
betaine ([19] and Table 1), with the exception of the South
American pseudocereals amaranth and quinoa. In the case
of individuals with coeliac disease or gluten intolerance who
are also at risk of NAFLD, regular consumption of these two
pseudocereals may be advisable.
Recently, Fardet proposed the concept of lipotropes, com-
pounds thatmay play a role in preventing excessive hepatic fat
accumulation [120], including betaine, choline, myo-inositol,
methionine,magnesium, niacin, pantothenic acid, folate, and
total polyphenol content. Cereal-based foods, and especially
whole grains, are considered the most economic source
of lipotropic compounds [121]. However, this hypothesis is
currently based on animal data and it remains to be seen
if the lipotropic index translates it to the clinical setting.
Nevertheless it is clear that whole grains are always higher
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in these “lipotropic” compounds compared to their refined
equivalents, and when cereals make up a large part of our
energy intake, this may have consequences for NAFLD.
Other compounds present in high amounts in cerealsmay
play a role in preventing NAFLD. In particular, whole grains
are rich in phenolic compounds, mainly ferulic acid. In vitro
and animal studies suggest that ferulic acid conjugates can
reduce inflammation via inhibition of the transcription factor
NF-𝜅B and activation of proinflammatory pathways [122].
However, ferulic acid itself had little effect in a Caco-2 cell
model of intestinal inflammation though flavonoids did [123].
A fermentedwhole grainwheat breadwas found to reduce ex-
vivo cytokine production in blood, and this was associated
with greater ferulic acid bioavailability [124]. In cereals, the
phenolic acids are mainly (>95%) bound to fibre and are
not thought to be released from the matrix during intestinal
transit, thus leading to a low bioavailability of <5% [125]. It
is possible that even if phenolic acids are not absorbed, they
do play a role in modulating gut microbiota and improving
the chemistry of the intestinal milieu [126]. While ferulic
acid is a strong antioxidant, it is unlikely that the amount
absorbed has ameaningful effect on overall antioxidant status
through classical mechanisms [127, 128]. Another group of
phenolic compounds, the alkylresorcinols (phenolic lipids),
is present in high amounts in wheat and rye and has around
60% absorption by humans [129]. There is relatively little
information about any bioactivity in vivo [130] although one
study where rats were fed rye alkylresorcinols found that high
doses (0.4% of total diet) led to a dramatic decrease in total
liver lipids and an increase in liver 𝛾-tocopherol via com-
petitive inhibition of CYP450-mediated 𝛽-oxidation [131]. In
adipocyte models, alkylresorcinols were also found to inhibit
triglyceride synthesis [132] and inhibit hormone sensitive
lipase-mediated-lipolysis of triglycerides [133], suggesting
that they may both prevent excessive triglyceride accumu-
lation and prevent elevated circulating concentrations of
nonesterified fatty acids (NEFA) [134]. Alkylresorcinol intake
was associated with decreased plasma NEFA after a whole
grain intervention [68] though more in vitro and in vivo
studies are needed to confirm this potential mechanism. Oats
contain phenolic analogues of the anti-inflammatory drug
tranilast, avenanthramides. Avenanthramides also have anti-
inflammatory properties in vivo [135], though concentrations
in oats are low, and a high intake of oats would likely be
required to observe an acute effect. Avenanthramides may in
part be responsible for the effect of oats in protecting against
ethanol damage to the liver of rodents, otherwise ascribed to
an improvement of the intestinal barrier [97].
It is also likely that the different components of whole
grains act together synergistically. A whole grain wheat diet
increased faecal Bifidobacteria populations in humans com-
pared to wheat bran [77], and whole grain wheat decreased
cholesterol in a rat model, whereas wheat bran did not [136].
It is also speculated that phenolic compounds and dietary
fibre from whole grains differentially interact with the host
microbiota to improve overall host-microbiota interactions
[126]. The synergy between the different components of the
whole grain may account for why they are associated with
reduced risk of a wide range of diseases.
Whole grain foods potentially contain a variety of anti-
nutrients and toxins, as the outer protective layer of the grain
is included, and this is exposed to soil, fungal infections,
and pesticides. In practice, cereal raw materials are strictly
monitored to ensure that known mycotoxins and pesticides
are below local thresholds of concern [137, 138], and millers
often remove the outer 1-2% of the grain before making
“whole grain” flour to substantially reduce the likelihood
of contaminants being present [139]. Whole grains are also
high in phytate, which decreases mineral bioavailability, both
micronutrientminerals and heavymetals [140], and rice bran
phytate has been demonstrated to reduce lead poisoning in
a rat model [141]. While contaminated grains could be a
source of toxins that could cause liver damage, there is no
population-based evidence to suggest that current thresholds
for monitoring contaminants are inadequate.
In the diet and NAFLD literature, there is some concern
that diets higher in carbohydrates may be linked to the
increased incidence of NAFLD [142, 143] and that low-
carbohydrate diets may lead to greater fat loss and improve-
ment in insulin sensitivity [29, 144]. However, these studies
do not describe the type of carbohydrate in the diet, nor
the origins. While sucrose, refined white wheat flour, whole
grain flour, and potatoes may all be classed as “carbohydrate
rich”, they all lead to different metabolic responses, even
before accounting for different food processing methods. We
therefore suggest that the source of carbohydrates may be
critical and that the greater nutrient content of whole grains
makes them a “positive” source of energy for people with
NAFLD compared to other carbohydrate rich foods that are
dietary staples in the Western diet and may exacerbate fatty
liver disease.
5. Conclusions
Presently the only empirically based dietary advice for
patients with NAFLD is to eat a hypoenergetic diet and
lose weight, and there is little evidence for what sort of
foods should be used to achieve this with the best outcome.
People who consume diets rich in whole grains tend to
have a lower risk of many of the comorbidities associated
with NAFLD, including NASH, and all whole grains contain
higher amounts of compounds which may help reduce liver
fat and protect against the inflammation that is thought to act
as the second hit that leads to the progression from steatosis
to NASH. Since there is no direct evidence that a whole grain
diet may help to protect or treat NAFLD, clinical studies
comparing whole grains with refined grains for preventing
and treatingNAFLD are needed. Given themultiple potential
mechanisms where whole grains may prevent or treat risk
factors associated with NAFLD (Figure 1), there is a good
basis to recommend that people with or at risk of NAFLD
should choose whole grains over refined grains in their diet.
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